MY151030A - Quinoline derivatives as antibacterial agents - Google Patents

Quinoline derivatives as antibacterial agents

Info

Publication number
MY151030A
MY151030A MYPI20063045A MY151030A MY 151030 A MY151030 A MY 151030A MY PI20063045 A MYPI20063045 A MY PI20063045A MY 151030 A MY151030 A MY 151030A
Authority
MY
Malaysia
Prior art keywords
alkyl
hydrogen
het
alkyloxy
alkylthio
Prior art date
Application number
Other languages
English (en)
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Jérôme Emile Georges Guillemont
Magali Madeleine Simone Motte
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MY151030A publication Critical patent/MY151030A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20063045 2005-06-28 2006-06-27 Quinoline derivatives as antibacterial agents MY151030A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05105769 2005-06-28

Publications (1)

Publication Number Publication Date
MY151030A true MY151030A (en) 2014-03-31

Family

ID=35445742

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20063045 MY151030A (en) 2005-06-28 2006-06-27 Quinoline derivatives as antibacterial agents

Country Status (33)

Country Link
US (2) US20100204270A1 (enExample)
EP (1) EP1898910B1 (enExample)
JP (1) JP5193859B2 (enExample)
KR (1) KR101423229B1 (enExample)
CN (1) CN101252928B (enExample)
AP (1) AP2733A (enExample)
AR (1) AR057654A1 (enExample)
AU (1) AU2006263884B2 (enExample)
BR (1) BRPI0612534B8 (enExample)
CA (1) CA2612623C (enExample)
CY (1) CY1118515T1 (enExample)
DK (1) DK1898910T3 (enExample)
EA (1) EA014163B1 (enExample)
ES (1) ES2606772T3 (enExample)
HR (1) HRP20161704T1 (enExample)
HU (1) HUE031268T2 (enExample)
IL (1) IL188394A (enExample)
JO (1) JO3270B1 (enExample)
LT (1) LT1898910T (enExample)
ME (1) ME02690B (enExample)
MX (1) MX2008000082A (enExample)
MY (1) MY151030A (enExample)
NO (1) NO341283B1 (enExample)
NZ (1) NZ564339A (enExample)
PL (1) PL1898910T3 (enExample)
PT (1) PT1898910T (enExample)
RS (1) RS55408B1 (enExample)
SG (1) SG166799A1 (enExample)
SI (1) SI1898910T1 (enExample)
TW (1) TWI392494B (enExample)
UA (1) UA91549C2 (enExample)
WO (1) WO2007000436A1 (enExample)
ZA (1) ZA200711149B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9790186B2 (en) 2009-07-21 2017-10-17 Trustees Of Dartmouth College Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection
AU2013254670B2 (en) 2012-04-27 2017-03-30 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
ES2576491T3 (es) 2012-04-27 2016-07-07 Janssen Pharmaceutica, N.V. Derivados de quinolina antibacterianos
CN105037497B (zh) * 2015-03-27 2018-06-26 中牧实业股份有限公司 一种恩拉霉素的提纯方法
WO2017035288A1 (en) * 2015-08-27 2017-03-02 Trustees Of Dartmouth College Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
SI1527050T1 (sl) * 2002-07-25 2010-08-31 Janssen Pharmaceutica Nv Kinolinski derivati in njihova uporaba kot mikobakterijski inhibitorji
MXPA06013888A (es) * 2004-05-28 2007-01-26 Janssen Pharmaceutica Nv Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos.
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis

Also Published As

Publication number Publication date
ES2606772T3 (es) 2017-03-27
PT1898910T (pt) 2016-11-16
NO20080481L (no) 2008-02-29
UA91549C2 (ru) 2010-08-10
JO3270B1 (ar) 2018-09-16
RS55408B1 (sr) 2017-04-28
HK1120734A1 (en) 2009-04-09
IL188394A (en) 2012-09-24
US20100204270A1 (en) 2010-08-12
AR057654A1 (es) 2007-12-12
EA200800152A1 (ru) 2008-06-30
DK1898910T3 (en) 2017-01-09
NO341283B1 (no) 2017-10-02
CA2612623A1 (en) 2007-01-04
AU2006263884B2 (en) 2013-01-10
HRP20161704T1 (hr) 2017-02-10
WO2007000436A1 (en) 2007-01-04
BRPI0612534A8 (pt) 2017-12-26
CN101252928B (zh) 2012-05-23
MX2008000082A (es) 2008-03-24
SG166799A1 (en) 2010-12-29
EA014163B1 (ru) 2010-10-29
BRPI0612534A2 (pt) 2010-11-23
BRPI0612534B8 (pt) 2021-05-25
US20130030017A1 (en) 2013-01-31
EP1898910B1 (en) 2016-09-28
CY1118515T1 (el) 2017-07-12
ZA200711149B (en) 2009-06-24
CA2612623C (en) 2016-09-27
HUE031268T2 (en) 2017-06-28
LT1898910T (lt) 2017-01-10
TW200738237A (en) 2007-10-16
AU2006263884A1 (en) 2007-01-04
BRPI0612534B1 (pt) 2020-04-22
JP2008546825A (ja) 2008-12-25
TWI392494B (zh) 2013-04-11
JP5193859B2 (ja) 2013-05-08
SI1898910T1 (sl) 2017-01-31
KR20080028460A (ko) 2008-03-31
PL1898910T3 (pl) 2017-03-31
CN101252928A (zh) 2008-08-27
EP1898910A1 (en) 2008-03-19
IL188394A0 (en) 2008-08-07
NZ564339A (en) 2011-02-25
AP2733A (en) 2013-09-30
ME02690B (me) 2017-10-20
KR101423229B1 (ko) 2014-07-25

Similar Documents

Publication Publication Date Title
TW200744594A (en) Quinoline derivatives as antibacterial agents
MY145845A (en) Treatment of latent tuberculosis
TW200744595A (en) Quinoline derivatives as antibacterial agents
NO20080499L (no) Kinolinderivater som antibakterielle midler
CY1113535T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
WO2005070924A8 (en) Substituted quinolines and their use as mycobacterial inhibitors
NO20080481L (no) Kinolinderivater som antibakterielle midler
NO20080501L (no) Kinolinderivater som antibakterielle midler
JO2695B1 (en) Treatment of latent TB